| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | AbbVie Inc. | 160,380,057 | 9.1% | EDGAR |
| SC 13G/A | 2024-01-25 | BlackRock Inc. | AbbVie Inc. | 143,180,060 | 8.1% | EDGAR |
| SC 13G/A | 2023-02-16 | BlackRock Inc. | AbbVie Inc. | 138,702,758 | 7.8% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | AbbVie Inc. | 158,317,552 | 9.0% | EDGAR |
| SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | AbbVie Inc. | 146,312,069 | 8.3% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | AbbVie Inc. | 128,197,555 | 7.3% | EDGAR |
| SC 13G/A | 2021-02-16 | Capital Research Global Investors | AbbVie Inc. | 37,921,062 | 2.1% | EDGAR |
| SC 13G/A | 2021-02-10 | VANGUARD GROUP INC | AbbVie Inc. | 142,563,074 | 8.1% | EDGAR |
| SC 13G/A | 2021-01-29 | BlackRock Inc. | AbbVie Inc. | 124,423,484 | 7.0% | EDGAR |
| SC 13G/A | 2020-02-14 | Capital Research Global Investors | AbbVie Inc. | 86,602,693 | 5.8% | EDGAR |
| SC 13G/A | 2020-02-12 | VANGUARD GROUP INC | AbbVie Inc. | 122,574,720 | 8.3% | EDGAR |
| SC 13G/A | 2020-02-05 | BlackRock Inc. | AbbVie Inc. | 98,593,810 | 6.7% | EDGAR |
| SC 13G/A | 2019-11-08 | Capital Research Global Investors | AbbVie Inc. | 94,861,327 | 6.4% | EDGAR |
| SC 13G/A | 2019-02-14 | VANGUARD GROUP INC | AbbVie Inc. | 120,583,425 | 8.0% | EDGAR |
| SC 13G/A | 2019-02-14 | Capital Research Global Investors | AbbVie Inc. | 173,568,243 | 11.5% | EDGAR |
| SC 13G/A | 2019-02-11 | VANGUARD GROUP INC | AbbVie Inc. | - | - | EDGAR |
| SC 13G/A | 2019-02-04 | BlackRock Inc. | AbbVie Inc. | 95,788,899 | 6.4% | EDGAR |
| SC 13G/A | 2018-02-14 | Capital Research Global Investors | AbbVie Inc. | 193,010,773 | 12.0% | EDGAR |
| SC 13G/A | 2018-02-08 | BlackRock Inc. | AbbVie Inc. | 101,322,201 | 6.3% | EDGAR |
| SC 13G/A | 2018-02-08 | VANGUARD GROUP INC | AbbVie Inc. | 119,852,562 | 7.5% | EDGAR |